Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LokkSign (SZC) in chronic hemodialysis patients with hyperkalemia
CTR20211885Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sodium zirconium cyclosilicate in hyperkalemia, end-stage kidney disease (ESKD), sponsored by AstraZeneca. Started Aug 2021; status: terminated.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on CTR20211885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211885.